Actelion reports positive Merit study results of macitentan to treat pulmonary hypertension

Swiss bio-technology company Actelion has reported positive results from its macitentan in the treatment of Inoperable chronic thromboembolic pulmonary hypertension (Merit) study of macitentan in patients with inoperable chronic thromboembolic pulmon …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news